文献速递临床生化临床免疫

依西美坦对雄烯二酮免疫测定的分析干扰

Analytical Interference of Exemestane With Androstenedione Immunoassays.
PubMed 文献 · Ann Lab Med · 2025-03-21

该多中心研究评估了接受依西美坦治疗的女性(N=15,25 mg/天)血清中雄烯二酮、睾酮、雌二醇、孕酮和17-羟孕酮的免疫测定干扰。所有4种免疫测定均显示雄烯二酮假性升高,且与血清依西美坦水平相关,体外实验证实由交叉反应导致。一种免疫测定在20%患者中雌二醇假性升高,但体外实验未证实与依西美坦或17-氢依西美坦交叉反应有关。

要点

  • 依西美坦治疗患者中,所有4种免疫测定均出现雄烯二酮假性升高,与血清依西美坦水平相关。
  • 体外实验证实依西美坦与雄烯二酮免疫测定存在交叉反应,导致假性升高。
  • 一种免疫测定在20%患者中雌二醇假性升高,但体外实验未证实与依西美坦或17-氢依西美坦交叉反应有关。

核心结论

  • 依西美坦与雄烯二酮免疫测定发生交叉反应,导致治疗患者结果假性升高。

研究设计与样本

  • 多中心研究,纳入接受依西美坦治疗(25 mg/天)的女性患者15例,测定血清雄烯二酮、睾酮、雌二醇、孕酮和17-羟孕酮。

主要发现

  • 所有4种免疫测定均显示雄烯二酮假性升高,且与血清依西美坦水平相关。
  • 一种免疫测定在20%患者中雌二醇假性升高,但体外实验未证实由依西美坦或17-氢依西美坦交叉反应导致。

关键数值与推荐

  • 依西美坦治疗患者中所有4种免疫测定均出现雄烯二酮假性升高。
  • 一种免疫测定在20%患者中雌二醇假性升高。

临床怎么用

  • 临床实验室应警惕接受依西美坦治疗患者的雄烯二酮免疫测定假性升高,必要时采用LC-MS确认。

局限性

  • 样本量小(N=15),仅评估了部分商业免疫测定,体外实验未完全解释雌二醇假性升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exemestane, an aromatase inhibitor commonly used for breast cancer treatment, shares structural similarities with sex steroids analyzed in clinical laboratories. We aimed to investigate the influence of exemestane cross-reactivity in the measurement of sex steroids across various immunoassays. METHODS: We conducted a multicenter study involving measurements of androstenedione, testosterone, estradiol, progesterone, and 17-hydroxyprogesterone in serum samples from women undergoing exemestane therapy (N=15; 25 mg/day). Measurements were performed using liquid chromatography-mass spectrometry (LC-MS) and various commercially available chemiluminescence immunoassays, ELISA, and radioimmunoassay. In-vitro cross-reactivity was assessed by adding exemestane and 17-hydroexemestane to serum samples. RESULTS: Patients undergoing exemestane therapy had markedly falsely elevated androstenedione results in all immunoassays evaluated (N=4), which correlated with serum exemestane levels. In-vitro experiments confirmed this interference to be caused by cross-reactivity with exemestane. Additionally, one immunoassay yielded falsely elevated estradiol results in 20% of patients. However, in-vitro experiments did not confirm this to be caused by cross-reactivity with exemestane or 17-hydroexemestane. CONCLUSIONS: Exemestane cross-reacts with androstenedione immunoassays, causing falsely elevated results in treated patients. This analytical interference may raise unnecessary concerns, leading to expensive diagnostic workups.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Giralt M, Ferrer R, Díaz-Troyano N, et al. Analytical Interference of Exemestane With Androstenedione Immunoassays. Ann Lab Med. 2025. PMID: 40114653. doi:10.3343/alm.2024.0362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。